Skip to main content
. 2023 Jan 30;7:e2200540. doi: 10.1200/PO.22.00540

FIG 2.

FIG 2.

Patient-level outcomes for 112 patients with molecularly characterized oligometastatic NSCLC. The latency between diagnosis and outcome, either last follow-up or death, is represented by the length of each bar shown. Mutation statuses for common mutations are provided. LCT, local consolidative therapy, NSCLC, non–small-cell lung cancer.